Dynavax Technologies is a California-based company in the biotechnology industry with a focus on developing novel vaccines. Its first commercial product was a Hepatitis B vaccine called HEPLISAV-B.It develops its medical solutions using Toll-like Receptor (TLR) technology.
The company entered into a partnership with Clover Biopharmaceuticals, a Chinese biotechnology company, to develop a vaccine candidate for COVID-19. The company's roll in the partnership includes technical expertise as well as CpG 1018, an adjuvant that is used in creating vaccines such as the company's own HEPLISAV-B.
Dynavax Technologies also partnered with Sinovac to combine its adjuvant CpG 1018 with Sinovac's chemically inactivated vaccine candidate for COVID-19.
Timeline
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
Covid 19 vaccine to be worked on by Dynavax, UQ and CEPI.
Web
March 3, 2020
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax Technologies Corporation
Web
March 24, 2020
The Next Big Thing In Biotech: Dynavax
Web
November 9, 2012